Weekly Analysts’ Ratings Updates for Geron (GERN)

A number of research firms have changed their ratings and price targets for Geron (NASDAQ: GERN):

• 3/12/2025 – Geron had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 3/12/2025 – Geron had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
• 2/27/2025 – Geron had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $4.00 price target on the stock, down previously from $9.00.
• 2/27/2025 – Geron had its price target lowered by analysts at Scotiabank from $6.00 to $4.00. They now have a “sector outperform” rating on the stock.
• 2/27/2025 – Geron was downgraded by analysts at B. Riley from a “buy” rating to a “neutral” rating. They now have a $2.00 price target on the stock, down previously from $3.50.
• 2/27/2025 – Geron had its price target lowered by analysts at Stifel Nicolaus from $8.00 to $4.00. They now have a “buy” rating on the stock.
• 2/27/2025 – Geron had its price target lowered by analysts at Needham & Company LLC from $7.00 to $5.00. They now have a “buy” rating on the stock.
• 2/26/2025 – Geron was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating.
• 2/18/2025 – Geron had its price target lowered by analysts at B. Riley from $5.50 to $3.50. They now have a “buy” rating on the stock.
• 1/13/2025 – Geron had its price target raised by analysts at Needham & Company LLC from $6.00 to $7.00. They now have a “buy” rating on the stock.

Geron Stock Performance

GERN opened at $1.77 on Thursday. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -5.53 and a beta of 0.53. The business’s 50-day moving average price is $2.69 and its two-hundred day moving average price is $3.62. Geron Co. has a 1 year low of $1.46 and a 1 year high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Equities analysts expect that Geron Co. will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Geron

A number of large investors have recently added to or reduced their stakes in the stock. Alternative Investment Advisors LLC. grew its position in Geron by 13.3% during the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 2,612 shares in the last quarter. Rovin Capital UT ADV grew its position in Geron by 26.9% during the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,660 shares in the last quarter. Xponance Inc. grew its position in Geron by 12.9% during the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,829 shares in the last quarter. US Bancorp DE grew its position in Geron by 68.4% during the third quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 7,429 shares in the last quarter. Finally, KBC Group NV grew its position in Geron by 45.1% during the fourth quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 7,592 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.